 Hoth Therapeutics, Inc. NASDAQ: HOTH, a biopharmaceutical company, today announced that it has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic BioLexa for Atopic Dermatitis. The ethics submission was made to the Bellberry Human Research Ethics Committee in Australia. 